Founded by Johns Hopkins neuroscientist Michela Gallagher in 2008, AgeneBio develops investigational therapeutics for neurological and psychiatric diseases, with a lead program aimed at treating mild cognitive impairment due to Alzheimer’s disease. The Baltimore company’s research centers on hippocampal overactivity and its role in memory loss and neurodegeneration. Its lead candidate, AGB101, is being evaluated in clinical trials and is not FDA approved; its safety and efficacy have not been established.
NeuroNascent, IncFounded by neuroscientist Judith Kelleher-Andersson, NeuroNascent is a privately held biotechnology company developing oral small-molecule therapies designed to stimulate the brain’s own neuron regeneration. Its lead candidate, NNI-362, has completed Phase 1a safety testing in healthy older adults and is being advanced for Alzheimer’s and Parkinson’s disease, while the company’s patented discovery platform also supports programs in other neurological disorders. The Clarksville, Maryland company is led by a team with deep experience in central nervous system drug development.CLARKSVILLE, MD
Cognition Therapeutics, IncCognition Therapeutics is a clinical-stage neuroscience company developing oral medicines for age-related neurodegenerative diseases, with its research centered on zervimesine (CT1812), an investigational therapy intended to protect synapses from toxic protein oligomers. The company brings 20 years of mechanistic, translational, and clinical research to Alzheimer’s disease and dementia with Lewy bodies, where its once-daily small-molecule approach is being evaluated in Phase 2 studies. Headquartered in Purchase, New York, Cognition also uses clinical research and patient-caregiver engagement to address conditions that have historically received limited investment.PURCHASE, NY
IGC Pharma, IncFrom its Potomac headquarters, IGC Pharma develops investigational therapies and AI tools for Alzheimer’s disease and related dementias. Its lead candidate, IGC-AD1, is being evaluated in the Phase 2 CALMA trial for agitation associated with Alzheimer’s dementia, while the company’s MINT-AD and aha™ platforms apply artificial intelligence to risk prediction and research-data harmonization. IGC Pharma operates an integrated international organization with manufacturing and processing in Vancouver, Washington, clinical research in Colombia, and accounting and analytics in India.POTOMAC, MD